FindTrial
Sign In

Prognostic Value of Radiomics-Based Body Composition Analysis for Postoperative Survival in Pancreatic Cancer

Prognostic Value of Radiomics-Based Body Composition Analysis for Postoperative Survival in Pancreatic Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092426
Enrollment
Unknown
Registered
2024-11-15
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Observation group:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Underwent radical resection for pancreatic cancer. 2. Pathologically diagnosed as pancreatic ductal adenocarcinoma. 3. Had preoperative enhanced CT scan data within one month prior to surgery.

Exclusion criteria

Exclusion criteria: 1. Coexistence of pancreatic cancer with malignant tumors at other sites 2. Received neoadjuvant chemotherapy or radiotherapy before surgery. 3. With poor imaging quality, not meeting the requirements for analysis.

Design outcomes

Primary

MeasureTime frame
Overall survival;—

Secondary

MeasureTime frame
Disease free survival;Tumor immune microenvironment.;—

Countries

China

Contacts

Public ContactKe Nengwen

West China Hospital, Sichuan University

kenengwen@scu.edu.cn+86 189 8060 6890

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026